Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Participants

23 mars 2016 uppdaterad av: Janssen-Cilag International NV

A Double-blind, Randomized, Controlled, 3-way Crossover, Pilot Study to Evaluate the Duration of Effects on Simulated Car Driving and Cognitive Performance After a Single Dose of JNJ-42847922, Zolpidem and Placebo in Healthy Subjects

The purpose of the study is to evaluate the effects of JNJ-42847922, compared to zolpidem and placebo, on driving performance as assessed by the mean difference of standard deviation of lateral position (SDLP) after forced awakening using a validated driving simulator test at 2, 4, 6 and 8 hours post-evening dose.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Detaljerad beskrivning

This is a single center, double-blind (neither Investigator nor participant knows which treatment the participant receives), randomized (study drug assigned by chance), 3-way cross-over (the same medications provided to all participants but in different sequence), pilot study in healthy male and female participants. Participants will be randomly assigned to 1 of 6 treatment and planning sequences. The study will consist of 3 parts: Screening Phase (between 21 days and 1 day prior to the first dose administration), a 3-way crossover double-blind, single dose treatment Phase and follow-up Phase (7 to 10 days after last dose administration). The maximum study duration for each participant will not exceed 7 weeks. The double-blind crossover treatment phase will consist of 3 treatment periods separated by a washout period of at least 3 days between dosing. Participants will receive either Treatment A (2 capsules of 20 milligram [mg] JNJ-42847922), Treatment B (10 mg zolpidem and 1 placebo capsule) or Treatment C (2 placebo capsules) in each treatment period. Driving performance will be assessed primarily by the mean difference of standard deviation of lateral position (SDLP) from an on road driving test. Participants' safety will be monitored throughout the study.

Studietyp

Interventionell

Inskrivning (Faktisk)

36

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 55 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  • Body mass index (BMI) (weight [kg]/height^2[m^2]) between 18 and 30 kg/m^2 (inclusive)
  • Men who are sexually active with a woman of childbearing potential must agree to use a condom, and all men must not donate sperm during the study and for 3 months after receiving the last dose of study drug. In addition, for men who have not had a vasectomy, their female partners should also use an appropriate method of birth control for at least the same duration
  • A woman of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test pre-dose on Day 1 of each period
  • A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for at least 3 months after receiving the last dose of study drug
  • Participant has a valid driving license for more than 3 years, has driven at least 5000 kilometer (km) in the past year and is driving a car regularly
  • Women of childbearing potential must practice a highly effective method of birth control consistent with local regulations regarding the use of birth control methods for participants participating in clinical studies (that is, one that results in a less than 1 percent per year failure rate when used consistently and correctly)

Exclusion Criteria:

  • Participant has clinically significant liver or renal insufficiency; cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic (including cataplexy and cognitive impairment), hematologic, rheumatologic, psychiatric, or metabolic disturbances. A significant primary sleep disorder is exclusionary
  • Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening as deemed appropriate by the investigator
  • Subject has a history of substance or alcohol use disorder according to Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5) criteria within 6 months before screening or positive test result(s) for alcohol and/or drugs of abuse (opiates [including methadone], cocaine, amphetamines, methamphetamines, cannabinoids, barbiturates, ecstasy and benzodiazepines) at screening or admission on Day 1 of each study period
  • Current suicidal or homicidal ideation/intent/behavior
  • Serology positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies (HCV) or Human immunodeficiency virus (HIV) antibodies

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Crossover tilldelning
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Group 1 (Sequence ABC)
Participants will receive Treatment A (2 capsules of 20 milligram [mg] JNJ-42847922) in Period 1, Treatment B (10 mg zolpidem and 1 placebo capsule) in Period 2 and Treatment C (2 placebo capsules) in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
Läkemedel: JNJ-42847922
JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule*20 mg) in one of the treatment periods.
Läkemedel: Zolpidem
Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
Läkemedel: Placebo
Matching Placebo will be administered orally.
Experimentell: Group 2 (Sequence BCA)
Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
Läkemedel: JNJ-42847922
JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule*20 mg) in one of the treatment periods.
Läkemedel: Zolpidem
Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
Läkemedel: Placebo
Matching Placebo will be administered orally.
Experimentell: Group 3 (Sequence CAB)
Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 2 and 6 hours after dosing.
Läkemedel: JNJ-42847922
JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule*20 mg) in one of the treatment periods.
Läkemedel: Zolpidem
Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
Läkemedel: Placebo
Matching Placebo will be administered orally.
Experimentell: Group 4 (Sequence ABC)
Participants will receive Treatment A in Period 1, Treatment B in Period 2 and Treatment C in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
Läkemedel: JNJ-42847922
JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule*20 mg) in one of the treatment periods.
Läkemedel: Zolpidem
Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
Läkemedel: Placebo
Matching Placebo will be administered orally.
Experimentell: Group 5 (Sequence BCA)
Participants will receive Treatment B in Period 1, Treatment C in Period 2 and Treatment A in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
Läkemedel: JNJ-42847922
JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule*20 mg) in one of the treatment periods.
Läkemedel: Zolpidem
Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
Läkemedel: Placebo
Matching Placebo will be administered orally.
Experimentell: Group 6 (Sequence CAB)
Participants will receive Treatment C in Period 1, Treatment A in Period 2 and Treatment B in Period 3 with a washout interval of at least 3 days between treatment periods. Participants randomized to this group will be assessed for pharmacodynamic testing at 4 and 8 hours after dosing.
Läkemedel: JNJ-42847922
JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule*20 mg) in one of the treatment periods.
Läkemedel: Zolpidem
Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
Läkemedel: Placebo
Matching Placebo will be administered orally.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Standard Deviation of Lateral Position (SDLP) Assessed From an On-road Driving Test
Tidsram: up to 8 hours post-dose
The SDLP will be measured from a simulated road tracking test over about 15 minutes. Instructed speed is 100 kilometer (km)/hour.
up to 8 hours post-dose

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Mean Lateral Position (MLP) Assessed From an On-road Driving Test
Tidsram: 2 to 8 hours post-dose
The MLP will be measured from a simulated road tracking test over about 15 minutes. Instructed speed is 100 kilometer (km)/hour.
2 to 8 hours post-dose
Distance-keeping Assessed From an On-road Driving Test
Tidsram: 2 to 8 hours post-dose
Distance-keeping will be measured from a simulated road tracking test over about 15 minutes. Instructed speed is 100 kilometer (km)/hour.
2 to 8 hours post-dose
Mean Speed (MS) Assessed From an On-road Driving Test
Tidsram: 2 to 8 hours post-dose
The MS will be measured from a simulated road tracking test over about 15 minutes. Instructed speed is 100 kilometer (km)/hour.
2 to 8 hours post-dose
Standard Deviation of Speed (SDS) Assessed From an On-road Driving Test
Tidsram: 2 to 8 hours post-dose
The SDS will be measured from a simulated road tracking test over about 15 minutes. Instructed speed is 100 kilometer (km)/hour.
2 to 8 hours post-dose
Number of Head movements Assessed From an On-road Driving Test
Tidsram: 2 to 8 hours post-dose
Number of head movements will be measured from a simulated road tracking test over about 15 minutes. Instructed speed is 100 kilometer (km)/hour.
2 to 8 hours post-dose
Reaction-time Assessed From an On-road Driving Test
Tidsram: 2 to 8 hours post-dose
Reaction-time will be assessed by 10 minutes of special and unexpected traffic events.
2 to 8 hours post-dose
Inhibition-time Assessed From an On-road Driving Test
Tidsram: 2 to 8 hours post-dose
Inhibition-time will be assessed by 10 minutes of special and unexpected traffic events.
2 to 8 hours post-dose
Alertness-time Assessed From an On-road Driving Test
Tidsram: 2 to 8 hours post-dose
Alertness-time will be assessed by 10 minutes of special and unexpected traffic events.
2 to 8 hours post-dose
Drive safety Score (DSS)
Tidsram: 2 to 8 hours post-dose
The DSS is a composite score of driving simulator behavior ranging from 0-10, related to actual driving performance.
2 to 8 hours post-dose
Subjective assessment of driving performance using visual analog scale
Tidsram: 2 to 8 hours post-dose
Participants indicated the perceived quality of their driving performance on a visual analog scale, which ranged from 0 ('I drove exceptionally poorly') to 20 ('I drove exceptionally well') around a midpoint of 'I drove normally'.
2 to 8 hours post-dose
Computerized Cognitive Test Battery: Detection (DET) Test
Tidsram: 2 to 8 hours post-dose
Simple reaction time task measuring processing speed; mean of the log10 transformed reaction times for correct responses (lower score = better performance).
2 to 8 hours post-dose
Computerized Cognitive Test Battery: Identification (IDN) Test
Tidsram: 2 to 8 hours post-dose
Choice reaction time paradigm measuring attention; mean of the log10 transformed reaction times for correct responses (lower score = better performance).
2 to 8 hours post-dose
Computerized Cognitive Test Battery: One Back (OBK) Test
Tidsram: 2 to 8 hours post-dose
Working memory measure; mean of the log10 transformed reaction times for correct responses (lower score = better performance).
2 to 8 hours post-dose
Computerized Cognitive Test Battery: One card learning
Tidsram: 2 to 8 hours post-dose
A visual recall test scored using arcsine transformation of the proportion of correct responses.
2 to 8 hours post-dose
Computerized Cognitive Test Battery: Trailmaking Test Form B (TMT-B)
Tidsram: 2 to 8 hours post-dose
TMT-B is a paper-and-pencil measure of divided attention and executive function (tracking, sequencing). The participant is instructed do draw a line to connect a set of 25 consecutively numbered and lettered circles, alternating sequentially between numbers and letters. The participant is instructed to work as quickly as possible while still maintaining accuracy. The test requires approximately 2 minutes to complete, alternate forms are available. Scores include time to completion and errors.
2 to 8 hours post-dose
Postural Stability Test
Tidsram: 2 to 8 hours post-dose
Postural stability will be measured by body sway meter which allows measurement of body movements in a single plane. Body sway is measured with a pot string meter (celesco) based on the Wright ataxiameter (Wright, 1971). With a string attached to the waist, all body movements over a period of time are integrated and expressed as millimeter sway. The total period of body sway measurement will be two minutes.
2 to 8 hours post-dose
Karolinska Sleepiness Scale (KSS) Score
Tidsram: 2 to 8 hours post-dose
The KSS is a participant-reported assessment used to rate sleepiness on a scale of 1 to 9, ranging from 1 (extremely alert) to 9 (very sleepy, great effort to keep awake, fighting sleep).
2 to 8 hours post-dose
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: up to Follow-up (7-10 days after last dose of study drug)
An AE was any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
up to Follow-up (7-10 days after last dose of study drug)
Relationship between duration of changes in driving ability and plasma concentrations of JNJ-42847922
Tidsram: Pre-dose and Day 1 post-dose
Relationship between duration of changes in driving ability and plasma concentrations of JNJ-42847922 will be reported.
Pre-dose and Day 1 post-dose

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Janssen-Cilag International NV

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart

1 november 2015

Primärt slutförande (Faktisk)

1 februari 2016

Avslutad studie (Faktisk)

1 februari 2016

Studieregistreringsdatum

Först inskickad

15 oktober 2015

Först inskickad som uppfyllde QC-kriterierna

15 oktober 2015

Första postat (Uppskatta)

19 oktober 2015

Uppdateringar av studier

Senaste uppdatering publicerad (Uppskatta)

24 mars 2016

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

23 mars 2016

Senast verifierad

1 mars 2016

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • CR108056
  • 42847922EDI1011 (Annan identifierare: Janssen-Cilag International NV)
  • 2015-004203-24 (EudraCT-nummer)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Kliniska prövningar på Friska

Kliniska prövningar på JNJ-42847922

Sök liknande försök

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

CROs by country

CROs in Rwanda

Betingelser

Sällsynta sjukdomar

Läkemedelsinterventioner

Kosttillskott

Sponsor / medarbetare

Platser

3
Prenumerera